Mast cell disorders (MCAS / mastocytosis / HαT)
Episodic multi-system mast-cell-mediator-release symptoms — flushing, urticaria, GI, cardiovascular, neuropsychiatric — under the umbrella of MCAS, systemic mastocytosis, and hereditary alpha-tryptasemia.
What changes during this transition
Mast-cell disorders are an underserved community with thin published peptide evidence and heavy community engagement. The diagnostic landscape itself is contested: the stricter Valent criteria (objective tryptase rise during episodes) yield far fewer diagnoses than the broader Molderings consensus criteria. Users arriving here may have a formal SM diagnosis with KIT D816V, an HαT genetic confirmation (TPSAB1 CNV per Lyons 2016), an MCAS workup in progress, or an MCAS-phenotype self-identification. The editorial register has to honor all four. The peptides surfaced here cluster into three editorial positions. The biologically-aligned candidate is **KPV** — α-MSH C-terminal tripeptide with preclinical mast-cell-stabilization evidence (Brzoska/Luger/Böhm body of work); the most defensible mechanistic story in the library for this trigger, though no MCAS-specific trial exists. The adjacent-symptom candidates are **BPC-157** (GI-dominant MCAS overlap), **Thymosin alpha-1** (autoimmune-overlap MCAS subset only), and **Selank** (the anxiety/dysautonomia overlap that is one of the most-overlooked components of patient experience). The hard contraindication anchor is **LL-37** — cathelicidins directly degranulate mast cells via MRGPRX2 (Befus 2002; Subramanian 2011), and any MCAS marketing claim for LL-37 is mechanistically wrong-direction. Standard of care is heavy and trial-backed: H1 + H2 antihistamines (often above standard dosing), mast-cell stabilizers (cromolyn, ketotifen), leukotriene modifiers (montelukast — with FDA 2020 neuropsychiatric black box), omalizumab for IgE-component cases, and for KIT D816V advanced SM the tyrosine kinase inhibitors midostaurin (Rydapt 2017) and avapritinib (Ayvakit 2021/2023 via PIONEER + EXPLORER trials). No peptide in the library has trial evidence in any mast-cell-disorder population — they slot as adjuncts only, never substitutes.
Important caveat
Mast-cell disorders require specialty allergy/immunology management, not peptide-clinic substitution — the diagnostic workup (tryptase, urine N-methylhistamine, urine 11β-PGF2α, leukotriene E4, KIT D816V mutation testing, TPSAB1 CNV for suspected HαT) and the established treatment ladder sit before any peptide adjunct. Anaphylaxis preparedness is non-negotiable: EpiPens current, written emergency plan, first peptide doses ideally in a setting where help is available. CRITICAL: Peptides that engage MRGPRX2 (notably LL-37/cathelicidins) are direct mast-cell degranulators — mechanistically the wrong direction; opioids, NSAIDs in sensitive subsets, iodinated contrast, and vancomycin remain known trigger categories that any new agent layers onto.
Peptides editorially relevant to mast cell disorders (mcas / mastocytosis / hαt)
4 peptides from the library — each evidence-tiered honestly.
- KPVTier 3
α-MSH C-terminal tripeptide
Short tripeptide fragment of a natural hormone (alpha-MSH). Appears to carry the anti-inflammatory signaling of the parent hormone without its pigmentation effects. Growing animal and early-human work, especially for inflammatory bowel disease.
- BPC-157Tier 3
Gastric pentadecapeptide
Extensively studied in rodents for tissue healing across tendon, gut, vascular, and CNS injury models. Human evidence is essentially absent — community framing far outpaces the data.
- Thymosin Alpha-1Tier 2
Immunomodulatory peptide
Approved in 30+ countries for chronic hepatitis B and C and as a sepsis adjunct in critically ill patients — but not in the US. Evidence quality varies sharply by indication, and the popular 'general immune support' framing has no clinical backing.
- SelankTier 3
Synthetic tuftsin analog (heptapeptide)
Russian-developed anxiolytic/nootropic peptide. Most clinical data is in Russian and methodologically thin by Western standards. Tier 3. Routes include intranasal — a natural pair with Juno's nasal-spray prep guide.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.